Evidence map›Paper›PMID 32382137›Full record

Trial reportMolecular psychiatry2021

Transcriptomic signatures of treatment response to the combination of escitalopram and memantine or placebo in late-life depression.

Adrienne Grzenda, Prabha Siddarth, Kelsey T Laird, Jillian Yeargin, Helen Lavretsky

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Molecular psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01902004 (Treatment of Geriatric Depression With Mild Cognitive Impairment), which is not on this map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01902004 phase4completednot on this map

Treatment of Geriatric Depression With Mild Cognitive Impairment: A Double-blind Placebo-Controlled Trial of Namenda (Memantine) Augmentation of Lexapro (Escitalopram) in Depressed Patients at Least 60 Years of Age

TypeinterventionalSponsorUniversity of California, Los AngelesRan2013 to 2019Enrolled115ConditionsMild Cognitive Impairment (MCI), DepressionArmsEscitalopram, Memantine, Placebo
3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 11 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Moderators of treatment response in late-life depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  5. Premature aging in serious mental illness.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Adrienne GrzendaJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Pscyhiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-5952-6953
Prabha SiddarthJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Pscyhiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Kelsey T LairdJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Pscyhiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0002-3194-2522
Jillian YearginJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Pscyhiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Helen LavretskyJane and Terry Semel Institute for Neuroscience and Human Behavior, Department of Pscyhiatry and Biobehavioral Sciences, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. hlavretsky@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Brain aging and treatment response in geriatric depressionR01MH097892 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2013 to 2017
$3.5M
Mentoring and Research in Translational Science of Integrative MedicineK24AT009198 · NCCIH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Helen Lavretsky · 2016 to 2026
$1.4M
Neurobiological Mechanisms of Treatment Response in Geriatric DepressionK24MH086481 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI LAVRETSKY, HELEN · 2010 to 2014
$906k
THE DESCRIPTION AND DEVELOPMENT OF EMOTION EXPRESSIONF32MH009198 · NIMH · UNIVERSITY OF DELAWARE · PI HAYNES, OSWALD M · 1985 to 1986
–
NCATS NIH HHS UL1 TR001881NCCIH NIH HHS K24 AT009198NIMH NIH HHS K24 MH086481NIMH NIH HHS R01 MH097892
6 · The paper itself

Abstract

Drugs that target glutamate neuronal transmission, such as memantine, offer a novel approach to the treatment of late-life depression, which is frequently comorbid with cognitive impairment. The results of our recently published double-blind, randomized, placebo-controlled trial of escitalopram or escitalopram/memantine in late-life depression with subjective memory complaints (NCT01902004) indicated no differences between treatments in depression remission, but additional benefits in cognition at 12-month follow-up with combination treatment. To identify pathways and biological functions uniquely induced by combination treatment that may explain cognitive improvements, we generated transcriptional profiles of remission compared with non-remission from whole blood samples. Remitters to escitalopram compared with escitalopram/memantine combination treatment display unique patterns of gene expression at baseline and 6 months after treatment initiation. Functional enrichment analysis demonstrates that escitalopram-based remission associates to functions related to cellular proliferation, apoptosis, and inflammatory response. Escitalopram/memantine-based remission, however, is characterized by processes related to cellular clearance, metabolism, and cytoskeletal dynamics. Both treatments modulate inflammatory responses, albeit via different effector pathways. Additional research is needed to understand the implications of these results in explaining the observed superior effects of combination treatment on cognition observed with prolonged treatment.

Indexed as

Major Depressive DisorderMemantineCitalopramDepressionDouble-Blind MethodEscitalopramHumansTranscriptomeTreatment OutcomeCitalopramEscitalopramMemantine

Identifiers

PMID32382137
PMCPMC9922535
OpenAlexW3021846059

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.